Cognition Therapeutics (CGTX)
(Delayed Data from NSDQ)
$0.72 USD
0.00 (0.31%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $0.72 0.00 (0.56%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Cognition Therapeutics, Inc. has a market cap of $44.25M, which represents its share price of $0.71 multiplied by its outstanding shares number of 61.99M. As a small-cap company, CGTX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CGTX 0.72 0.00(0.31%)
Will CGTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CGTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGTX
Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
CGTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CGTX
Cognition Therapeutics presents data at AAIC on CT1812 in dementia
Cognition Therapeutics (CGTX) Showcases Promising Study Results at AAIC 2025
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of ...
Cognition Therapeutics (CGTX) Phase 2 Study Reveals Alzheimer's Drug Progress | CGTX Stock News
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of ...